Drug Shortage Report for TEVA-NARATRIPTAN
Report ID | 1137 |
Drug Identification Number | 02314304 |
Brand name | TEVA-NARATRIPTAN |
Common or Proper name | NARATRIPTAM HCL |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | NARATRIPTAN |
Strength(s) | 2.5MG |
Dosage form(s) | TABLET |
Route of administration | ORAL |
Packaging size | 8 |
ATC code | N02CC |
ATC description | ANTIMIGRAINE PREPARATIONS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2015-10-15 |
Estimated end date | 2018-02-28 |
Actual end date | 2018-03-13 |
Shortage status | Resolved |
Updated date | 2018-03-14 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v9 | 2018-03-14 | English | Compare |
v8 | 2018-03-13 | French | Compare |
v7 | 2018-03-13 | English | Compare |
v6 | 2017-11-06 | French | Compare |
v5 | 2017-11-06 | English | Compare |
v4 | 2017-03-13 | French | Compare |
v3 | 2017-03-13 | English | Compare |
v2 | 2017-03-13 | French | Compare |
v1 | 2017-03-13 | English | Compare |
Showing 1 to 9 of 9